quantisnow
FeedTopReportsPricing
⌘K
Live feed
07:50:00·1h
PRRelease
Lantern Pharma Inc. logo

Lantern Pharma to Debut Public Demonstration of withZeta.ai - A Platform to Conquer Rare Cancers on April 30 Following AACR 2026 Scientific Debut

LTRN· Lantern Pharma Inc.
Health Care
Original source

Companies

  • LTRN
    Lantern Pharma Inc.
    Health Care

Recent analyst ratings

  • Mar 11UpdateHC Wainwright & Co.$36.00
  • Nov 2UpdateHC Wainwright & Co.$34.00
  • Oct 7UpdateHC Wainwright & Co.$32.00

Related

  • PR4d
    Emerging Data for Lantern Pharma's Investigational Drug LP-300 Demonstrates 8.3-Month Median Progression-Free Survival in Patients with EGFR L858R Lung Cancer After Targeted Therapy Failure — With No Added Toxicity
  • PR10d
    Lantern Pharma Launches withZeta.ai — the World's First Multi-Agentic A.I. Co-Scientist for Rare Cancer Drug Discovery & Development — Subscriptions Now Open; Debut Events at Nasdaq MarketSite on 4/16 and at AACR 2026 from 4/17 to 4/22
  • SEC14d
    Lantern Pharma Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
  • SEC20d
    SEC Form SCHEDULE 13G filed by Lantern Pharma Inc.
  • PR22d
    Lantern Pharma Invites Investors, Analysts & Shareholders to Experience the Future of Drug Discovery via a Live Demo of withZeta.ai — the World's First Multi-Agentic Co-Scientist for Rare Cancers — 8:30 AM Eastern, April 9, 2026
  • SEC24d
    SEC Form 424B5 filed by Lantern Pharma Inc.
  • SEC24d
    SEC Form 10-K filed by Lantern Pharma Inc.
  • SEC24d
    Lantern Pharma Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022